ReNeuron Group PLC - Bridgend, Wales-based cell-based therapeutics - Appoints Mark Evans, chair of 16% shareholder Obotritia Capital KGaA, as non-executive director. Says ReNeuron and Obotritia sign relationship agreement to ensure independence of ReNeuron. Evans doesn't control the investment decisions of Obotritia, but separately from Obotritia has a 0.1% direct interest in ReNeuron and 1.7% via investment firms Partners Investment Co LLP and Albermarle Life Sciences LLP. ReNeuron promotes Non-Executive Director Tim Corn to be new chair, as John Berriman, Simon Cartmell and Claudia D'Augusta all step down. ReNeuron had said late last month it intended to reduce the number of non-executive directors on its board to four from six.
Current stock price: 111.00 pence
Year-to-date change: down 25%
By Tom Waite; thomaslwaite@alliancenews.com
Copyright 2020 Alliance News Limited. All Rights Reserved.
Reneuron (RENE)